(ALC) Alcon - Ratings and Ratios
Surgical Equipment, IOLs, Contact Lenses, Dry Eye Drops, Vitreoretinal Tools
EPS (Earnings per Share)
Revenue
| Risk via 10d forecast | |
|---|---|
| Volatility | 24.2% |
| Value at Risk 5%th | 37.5% |
| Relative Tail Risk | -5.90% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.46 |
| Alpha | -22.22 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.271 |
| Beta | 0.716 |
| Beta Downside | 0.681 |
| Drawdowns 3y | |
|---|---|
| Max DD | 28.24% |
| Mean DD | 8.82% |
| Median DD | 8.34% |
Description: ALC Alcon September 29, 2025
Alcon Inc. (NYSE: ALC) is a global eye-care company headquartered in Geneva, Switzerland, operating through two primary segments: Surgical and Vision Care. The Surgical segment delivers a full suite of intra-ocular lenses (IOLs), implantable devices, and consumables for cataract and vitreoretinal procedures, while Vision Care focuses on contact lenses, ocular-health products, and over-the-counter eye-care items.
In the Surgical arena, Alcon’s portfolio includes the Centurion and LenSx laser systems, the Verion digital marker, the ARGOS biometer, and the NGENUITY 3-D visualization platform, alongside a range of monofocal, toric, and presbyopia-correcting IOLs delivered via AutonoMe and UltraSert injection systems. The company also supplies vitreoretinal solutions such as the Constellation vision system, MIVS instruments, and Hypervit vitrectomy probes, as well as refractive-surgery lasers (WaveLight) and the Contoura Vision platform for LASIK.
Alcon’s Vision Care segment offers daily disposable, reusable, and color-enhancing contact lenses, plus ocular-health products covering dry eye, allergies, glaucoma, lens care solutions, ocular vitamins, and redness relievers. This breadth allows cross-selling opportunities between surgical patients and long-term contact-lens users.
Key performance indicators from the most recent fiscal year show total revenue of approximately $8.5 billion, with the Surgical segment contributing roughly 55 % and growing at a 4 % CAGR over the past three years, driven by an aging global population and rising cataract surgery rates. The Vision Care segment posted a 6 % YoY increase in contact-lens sales, supported by premium-lens pricing power and expanding emerging-market penetration. Macro-level drivers include favorable Medicare reimbursement trends for cataract procedures and ongoing demand for refractive-surgery solutions as consumer preference for spectacle-free vision rises.
For a deeper, data-driven assessment of Alcon’s valuation and risk profile, you may find it useful to explore the analytics available on ValueRay.
ALC Stock Overview
| Market Cap in USD | 38,708m |
| Sub-Industry | Health Care Equipment |
| IPO / Inception | 2019-04-09 |
| Return 12m vs S&P 500 | -21.2% |
| Analyst Rating | 4.33 of 5 |
ALC Dividends
| Metric | Value |
|---|---|
| Dividend Yield | 0.44% |
| Yield on Cost 5y | 0.54% |
| Yield CAGR 5y | 7.93% |
| Payout Consistency | 99.5% |
| Payout Ratio | 11.7% |
ALC Growth Ratios
| Metric | Value |
|---|---|
| CAGR 3y | 3.56% |
| CAGR/Max DD Calmar Ratio | 0.13 |
| CAGR/Mean DD Pain Ratio | 0.40 |
| Current Volume | 1882.8k |
| Average Volume | 1970.6k |
Piotroski VR‑10 (Strict, 0-10) 5.0
| Net Income (1.05b TTM) > 0 and > 6% of Revenue (6% = 611.1m TTM) |
| FCFTA 0.05 (>2.0%) and ΔFCFTA 0.49pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 32.79% (prev 39.58%; Δ -6.79pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.07 (>3.0%) and CFO 2.05b > Net Income 1.05b (YES >=105%, WARN >=100%) |
| Net Debt (3.74b) to EBITDA (1.44b) ratio: 2.59 <= 3.0 (WARN <= 3.5) |
| Current Ratio 2.12 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (495.9m) change vs 12m ago -0.36% (target <= -2.0% for YES) |
| Gross Margin 55.12% (prev 55.50%; Δ -0.38pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 32.93% (prev 32.15%; Δ 0.78pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 2.11 (EBITDA TTM 1.44b / Interest Expense TTM 199.8m) >= 6 (WARN >= 3) |
ValueRay F-Score (Strict, 0-100) 58.69
| 1. Piotroski 5.0pt |
| 2. FCF Yield 3.61% |
| 3. FCF Margin 15.05% |
| 4. Debt/Equity 0.24 |
| 5. Debt/Ebitda 2.59 |
| 6. ROIC - WACC (= -6.39)% |
| 7. RoE 4.77% |
| 8. Rev. Trend 88.69% |
| 9. EPS Trend 54.13% |
What is the price of ALC shares?
Over the past week, the price has changed by -4.53%, over one month by -0.54%, over three months by -7.39% and over the past year by -11.91%.
Is ALC a buy, sell or hold?
- Strong Buy: 15
- Buy: 6
- Hold: 6
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the ALC price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 95.2 | 26.9% |
| Analysts Target Price | 95.2 | 26.9% |
| ValueRay Target Price | 71.5 | -4.8% |
ALC Fundamental Data Overview November 16, 2025
P/E Trailing = 36.9762
P/E Forward = 22.1729
P/S = 3.8005
P/B = 1.6792
P/EG = 2.1018
Beta = 0.694
Revenue TTM = 10.19b USD
EBIT TTM = 421.1m USD
EBITDA TTM = 1.44b USD
Long Term Debt = 4.54b USD (from longTermDebt, last fiscal year)
Short Term Debt = 648.3m USD (from shortTermDebt, last quarter)
Debt = 5.23b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 3.74b USD (from netDebt column, last quarter)
Enterprise Value = 42.45b USD (38.71b + Debt 5.23b - CCE 1.50b)
Interest Coverage Ratio = 2.11 (Ebit TTM 421.1m / Interest Expense TTM 199.8m)
FCF Yield = 3.61% (FCF TTM 1.53b / Enterprise Value 42.45b)
FCF Margin = 15.05% (FCF TTM 1.53b / Revenue TTM 10.19b)
Net Margin = 10.28% (Net Income TTM 1.05b / Revenue TTM 10.19b)
Gross Margin = 55.12% ((Revenue TTM 10.19b - Cost of Revenue TTM 4.57b) / Revenue TTM)
Gross Margin QoQ = 55.78% (prev 53.47%)
Tobins Q-Ratio = 1.35 (Enterprise Value 42.45b / Total Assets 31.49b)
Interest Expense / Debt = 0.97% (Interest Expense 51.0m / Debt 5.23b)
Taxrate = 16.25% (46.0m / 283.0m)
NOPAT = 352.7m (EBIT 421.1m * (1 - 16.25%))
Current Ratio = 2.12 (Total Current Assets 6.33b / Total Current Liabilities 2.99b)
Debt / Equity = 0.24 (Debt 5.23b / totalStockholderEquity, last quarter 22.06b)
Debt / EBITDA = 2.59 (Net Debt 3.74b / EBITDA 1.44b)
Debt / FCF = 2.44 (Net Debt 3.74b / FCF TTM 1.53b)
Total Stockholder Equity = 21.93b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.32% (Net Income 1.05b / Total Assets 31.49b)
RoE = 4.77% (Net Income TTM 1.05b / Total Stockholder Equity 21.93b)
RoCE = 1.59% (EBIT 421.1m / Capital Employed (Equity 21.93b + L.T.Debt 4.54b))
RoIC = 1.33% (NOPAT 352.7m / Invested Capital 26.58b)
WACC = 7.72% (E(38.71b)/V(43.94b) * Re(8.65%) + D(5.23b)/V(43.94b) * Rd(0.97%) * (1-Tc(0.16)))
Discount Rate = 8.65% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.40%
[DCF Debug] Terminal Value 79.50% ; FCFE base≈1.45b ; Y1≈1.79b ; Y5≈3.06b
Fair Price DCF = 94.23 (DCF Value 46.29b / Shares Outstanding 491.2m; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 54.13 | EPS CAGR: 25.83% | SUE: 0.46 | # QB: 0
Revenue Correlation: 88.69 | Revenue CAGR: 6.99% | SUE: 0.45 | # QB: 0
Additional Sources for ALC Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle